Abeona Therapeutics Inc vs Mercadolibre Inc — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Mercadolibre Inc trades at $1,927.01 (market cap $98.35B). The key difference: Mercadolibre Inc is far larger — about 233.5× Abeona Therapeutics Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | MELI | |
|---|---|---|
Market Cap | $421.19M | $98.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $2.51K |
52-Week Low | $4.17 | $1.55K |
Enterprise Value | $276.10M | $106.00B |
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →